A study testing whether a new weekly shot, tirzepatide, can help people lose weight.
Recruiting now. Registry record last updated April 15, 2026.
- Who can join
- Adults 50+, have obesity, BMI 30+.
- What you take
- tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The study runs about 14 months.
- What you get
- Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
What this study is for
Primary condition: Obesity Prevention. Also studied in: Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss.
Full scientific study title: Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults.
Who can join
Adults 50+, have obesity, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Men and postmenopausal women aged 50 years or older.
- Body Mass Index (BMI) ≥30 kg/m².
- Untreated HbA1c \<6.5% at baseline.
- Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.
- Able to provide informed consent and participate in all study assessments.
Key exclusion criteria
- Active diagnosis of type 2 diabetes mellitus (T2DM), defined by active use of glucose-lowering medications or hemoglobin A1c ≥ 6.5%.
- Body Mass Index (BMI) ≥ 40 kg/m².
- Moderate to severe gastroesophageal reflux disease based on patient history.
- Inability to comply with the treatment protocol or to understand the consent form.
- Chronic Kidney Disease (CKD) Stage 4.
Where this trial is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Texas1 site
- University of Texas Health Science Center at San AntonioSan Antonio, TexasShreya Raoraos4@uthscsa.edu
Timeline
Started enrolling: April 1, 2026. Expected completion: June 1, 2027. Last updated on ClinicalTrials.gov: April 15, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
